Literature DB >> 16118349

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.

J Macías1, J A Girón-González, M González-Serrano, D Merino, P Cano, J A Mira, A Arizcorreta-Yarza, J Ruíz-Morales, J M Lomas-Cabeza, J A García-García, J E Corzo, J A Pineda.   

Abstract

BACKGROUND: Liver biopsy is an invasive technique with associated major complications. There is no information on the validity of five non-invasive indexes based on routinely available parameters, estimated and validated in hepatitis C virus (HCV) monoinfected patients, in human immunodeficiency virus (HIV)/HCV coinfected patients. AIM: To validate these predictive models of liver fibrosis in HIV/HCV coinfected patients. PATIENTS: A total of 357 (90%) of 398 patients from five hospitals were investigated, who underwent liver biopsy and who had complete data to validate all of the models considered.
METHODS: The predictive accuracy of the indexes was tested by measuring areas under the receiver operating characteristic curves. Diagnostic accuracy was calculated by estimating sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values.
RESULTS: The models performed better when liver biopsies>or=15 mm were used as reference. In this setting, the Forns and Wai indexes, models aimed at discriminating significant fibrosis, showed PPV of 94% and 87%, respectively. Using these models, 27-34% of patients could benefit from exclusion of liver biopsy. If both models were applied sequentially, 41% of liver biopsies could be spared. The indexes aimed at predicting cirrhosis achieved NPV of up to 100%. However, they showed very low PPV.
CONCLUSIONS: The diagnostic accuracy of these models was lower in HIV/HCV coinfected patients than in the validation studies performed in HCV monoinfected patients. However, simple fibrosis tests may render liver biopsy unnecessary in deciding anti-HCV treatment in over one third of patients with HIV infection and chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118349      PMCID: PMC1856097          DOI: 10.1136/gut.2005.065904

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Revelance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus.

Authors:  C Renou; P Muller; E Jouve; J J Bertrand; A Raoult; T Benderriter; P Halfon
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

Review 2.  AGA technical review on the evaluation of liver chemistry tests.

Authors:  Richard M Green; Steven Flamm
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

3.  Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis.

Authors:  R D Goldin; J G Goldin; A D Burt; P A Dhillon; S Hubscher; J Wyatt; N Patel
Journal:  J Hepatol       Date:  1996-11       Impact factor: 25.083

4.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

Authors:  C S Graham; L R Baden; E Yu; J M Mrus; J Carnie; T Heeren; M J Koziel
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

5.  Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C.

Authors:  T F Imperiale; A T Said; O W Cummings; L J Born
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

6.  Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

Authors:  J F Cadranel; P Rufat; F Degos
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

7.  The role of liver biopsy in chronic hepatitis C.

Authors:  S Saadeh; G Cammell; W D Carey; Z Younossi; D Barnes; K Easley
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

8.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Authors:  Thomas B Kelleher; Shruti H Mehta; Ramakrishnan Bhaskar; Mark Sulkowski; Jacquie Astemborski; David L Thomas; Richard E Moore; Nezam H Afdhal
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

9.  Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

Authors:  M Bonacini; G Hadi; S Govindarajan; K L Lindsay
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

10.  Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

Authors:  Carolin Lackner; Gerd Struber; Bernadette Liegl; Sebastian Leibl; Petra Ofner; Csilla Bankuti; Bernd Bauer; Rudolf E Stauber
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

View more
  34 in total

1.  Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients.

Authors:  Giovanni Mazzola; Lucia Adamoli; Vincenza Calvaruso; Fabio Salvatore Macaluso; Pietro Colletti; Sergio Mazzola; Adriana Cervo; Marcello Trizzino; Francesco Di Lorenzo; Chiara Iaria; Tullio Prestileo; Ambrogio Orlando; Vito Di Marco; Antonio Cascio
Journal:  Infection       Date:  2018-12-05       Impact factor: 3.553

Review 2.  Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched.

Authors:  M Pinzani
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

3.  Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.

Authors:  Valentina Li Vecchi; Maurizio Soresi; Claudia Colomba; Giovanni Mazzola; Pietro Colletti; Maurizio Mineo; Paola Di Carlo; Emanuele La Spada; Giovanni Vizzini; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 4.  Advances in the management of HIV/HCV coinfection.

Authors:  Mattias Mandorfer; Philipp Schwabl; Sebastian Steiner; Thomas Reiberger; Markus Peck-Radosavljevic
Journal:  Hepatol Int       Date:  2016-01-12       Impact factor: 6.047

5.  Use of the AST to platelet ratio index in HCV/HIV co-infected patients.

Authors:  A G Singal; L V Thomassen; D R Gretch; M C Shuhart
Journal:  Aliment Pharmacol Ther       Date:  2011-01-05       Impact factor: 8.171

Review 6.  Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

Authors:  Bassem Matta; Tzu-Hao Lee; Keyur Patel
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

7.  Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus.

Authors:  Adeel A Butt; Joel Tsevat; Anthony C Leonard; Obaid S Shaikh; Deborah McMahon; Uzma A Khan; Zachariah Dorey-Stein; Vincent Lo Re
Journal:  Int J Infect Dis       Date:  2008-11-06       Impact factor: 3.623

Review 8.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

9.  Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

Authors:  Michelle DallaPiazza; Valerianna K Amorosa; Russell Localio; Jay R Kostman; Vincent Lo Re
Journal:  BMC Infect Dis       Date:  2010-05-13       Impact factor: 3.090

10.  Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?

Authors:  Salvador Resino; José M Bellón; Cristina Asensio; Dariela Micheloud; Pilar Miralles; Ana Vargas; Pilar Catalán; Juan C López; Emilio Alvarez; Jaime Cosin; Raquel Lorente; María A Muñoz-Fernández; Juan Berenguer
Journal:  BMC Infect Dis       Date:  2010-08-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.